ArticleScientific reports2025
Hexahydrocurcumin suppresses hepatocellular carcinoma by regulating TRIM23/MBNL1 pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ginger-Derived Exosome-Like Nanoparticles: The Effect of Extraction Methods on Metabolites and in vitro Anti-Lung Cancer Activity.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) ranks among the most prevalent malignant tumors worldwide, characterized by high mortality rates. TRIM23, an E3 ubiquitin ligase, represents a potential molecular target for anticancer drug development. Additionally, Hexahydrocurcumin (HHC) exhibits notable anticancer activity as a natural product. Here, we aimed to investigate HHC's anti-tumor role in HCC. Molecular docking assays and Cellular thermal shift assays were employed to predict HHC's potential targeting of TRIM23. Immunofluorescence and western blot analyses were conducted to assess HHC's inhibition of TRIM23 expression. Wound-healing, clone formation, and transwell assays were used to evaluate its anti-tumor efficacy. Quantitative proteome analysis and co-immunoprecipitation (Co-IP) were employed to explore and verify HHC's potential mechanism in HCC cells. Subcutaneous HCC tumor-bearing mice were used to further validate HHC's function in vivo. Public databases confirmed TRIM23 as a potential biomarker of HCC, associated with poor prognosis. Molecular docking and Cellular thermal shift assays confirmed HHC as a direct inhibitor of TRIM23. Subsequent in vitro assays demonstrated HHC's ability to impede HCC cell function. Quantitative proteome analysis revealed upregulation of MBNL1, a tumor suppressor, in HHC-treated HCC cells. Rescue analysis further demonstrated MBNL1 as a substrate of TRIM23, directly influencing the phenotypic outcomes of HHC-treated cells. Additionally, subcutaneous HCC tumor-bearing mice confirmed HHC's efficacy in vivo. Our findings underscore TRIM23 as a promising therapeutic target for HCC treatment, with HHC emerging as an effective therapeutic agent by targeting the TRIM23/MBNL1 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.